Literature DB >> 11200773

Progression of premalignant MCF10AT generates heterogeneous malignant variants with characteristic histologic types and immunohistochemical markers.

L B Strickland1, P J Dawson, S J Santner, F R Miller.   

Abstract

The MCF10AT premalignant human breast epithelial cells form benign ductal structures in immunodeficient mice which sporadically progress to carcinoma in situ and invasive cancers of different histologic types. MCF10CA1 cell lines are malignant variants derived by serially passing small pieces of tumors in athymic mice before establishing cells in culture. As these MCF10CA1 variants gave rise to heterogeneous tumors, some cell lines were cloned. Inoculated into immunodeficient mice, these variants produce squamous carcinomas with an undifferentiated component or adenocarcinomas also with an undifferentiated component. Immunohistochemistry utilized antibodies against DF3, c-erbB-2, cyclin Dl, m keratin, p keratin, p53, B72.3 and estrogen receptor. We detected characteristic patterns for squamous carcinomas, for adenocarcinomas, and for each undifferentiated component, that is the undifferentiated components of the squamous and glandular carcinomas were distinct. Only adenocarcinomas were focally ER positive. One uncloned variant that produced cancers with a glandular component, MCF10CA1h, was cloned and cells were injected into mice. This clone produced only undifferentiated carcinomas that, compared to tumors formed by the parental uncloned variant, had lost ER, DF3 and c-erbB-2 expression, but more strongly expressed p53. Our data demonstrate the potential of the premalignant MCF10AT model to generate heterogeneity, including both estrogen receptor-positive as well as estrogen receptor-negative tumors, during progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200773     DOI: 10.1023/a:1026562720218

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  44 in total

1.  Primary cilia are decreased in breast cancer: analysis of a collection of human breast cancer cell lines and tissues.

Authors:  Kun Yuan; Natalya Frolova; Yi Xie; Dezhi Wang; Leah Cook; Yeon-Jin Kwon; Adam D Steg; Rosa Serra; Andra R Frost
Journal:  J Histochem Cytochem       Date:  2010-06-07       Impact factor: 2.479

2.  SDPR functions as a metastasis suppressor in breast cancer by promoting apoptosis.

Authors:  Sait Ozturk; Panagiotis Papageorgis; Chen Khuan Wong; Arthur W Lambert; Hamid M Abdolmaleky; Arunthathi Thiagalingam; Herbert T Cohen; Sam Thiagalingam
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-06       Impact factor: 11.205

3.  SWI/SNF chromatin remodeling enzyme ATPases promote cell proliferation in normal mammary epithelial cells.

Authors:  Nathalie Cohet; Kathleen M Stewart; Rajini Mudhasani; Ananthi J Asirvatham; Chandrashekara Mallappa; Karen M Imbalzano; Valerie M Weaver; Anthony N Imbalzano; Jeffrey A Nickerson
Journal:  J Cell Physiol       Date:  2010-06       Impact factor: 6.384

4.  Krüppel-like factor 4 inhibits tumorigenic progression and metastasis in a mouse model of breast cancer.

Authors:  Jennifer L Yori; Darcie D Seachrist; Emhonta Johnson; Kristen L Lozada; Fadi W Abdul-Karim; Lewis A Chodosh; William P Schiemann; Ruth A Keri
Journal:  Neoplasia       Date:  2011-07       Impact factor: 5.715

5.  Differentiation of cancer cells in two-dimensional and three-dimensional breast cancer models by Raman spectroscopy.

Authors:  Nur P Damayanti; Yi Fang; Mukti R Parikh; Ana Paula Craig; Julia Kirshner; Joseph Irudayaraj
Journal:  J Biomed Opt       Date:  2013-11       Impact factor: 3.170

6.  Synthetic triterpenoids can protect against toxicity without reducing the efficacy of treatment with Carboplatin and Paclitaxel in experimental lung cancer.

Authors:  Karen T Liby
Journal:  Dose Response       Date:  2013-08-01       Impact factor: 2.658

7.  Transforming growth factor-beta can suppress tumorigenesis through effects on the putative cancer stem or early progenitor cell and committed progeny in a breast cancer xenograft model.

Authors:  Binwu Tang; Naomi Yoo; Mary Vu; Mizuko Mamura; Jeong-Seok Nam; Akira Ooshima; Zhijun Du; Pierre-Yves Desprez; Miriam R Anver; Aleksandra M Michalowska; Joanna Shih; W Tony Parks; Lalage M Wakefield
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

8.  Smad signaling is required to maintain epigenetic silencing during breast cancer progression.

Authors:  Panagiotis Papageorgis; Arthur W Lambert; Sait Ozturk; Fangming Gao; Hongjie Pan; Upender Manne; Yuriy O Alekseyev; Arunthathi Thiagalingam; Hamid M Abdolmaleky; Marc Lenburg; Sam Thiagalingam
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

9.  Multiphoton spectral analysis of benzo[a]pyrene uptake and metabolism in breast epithelial cell lines.

Authors:  Rola Barhoumi; Jeffrey M Catania; Alan R Parrish; Igbal Awooda; Evelyn Tiffany-Castiglioni; Stephen Safe; Robert C Burghardt
Journal:  J Toxicol Sci       Date:  2009-02       Impact factor: 2.196

Review 10.  Xenograft models of premalignant breast disease.

Authors:  F R Miller
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.